Use of sacubitril/valsartan As ‘bridge to transplant’ in Patients With end-stage Hypertrophic Cardiomyopathy

References

• Vardeny O , MillerR, SolomonSD. Combined neprilysin and renin–angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail., 2(6), 663–670 (2016).
   Web of Science ®Google Scholar
• Gu J , NoeA, ChandraPet al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol., 50(4), 401–414 (2016).
   Google Scholar
• PARADIGM-HF Investigators and Committees . McMurrayJJ, PackerM, DesaiASet al.Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 371(11), 993–1004 (2016).
   Web of Science ®Google Scholar
• Ponikowski P , VoorsAA, AnkerSDet al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 18(8), 891–975 (2016).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136(6), e137–e161 (2017).
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA , O’MearaE, McDonaldMet al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can. J. Cardiol., 33(11), 1342–1433 (2017).
   PubMed Web of Science ®Google Scholar
• Elliott PM , AnastasakisA, BorgerMAet al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J., 35(39), 2733–2779 (2014).
   PubMed Web of Science ®Google Scholar
• Gersh BJ , MaronBJ, BonowROet al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons. J. Am. Coll. Cardiol., 58(25), 212–260 (2011).
   PubMed Web of Science ®Google Scholar
• Mehra MR , CanterCE, HannanMMet al. The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J. Heart Lung Transplant., 35(1), 1–23 (2016).
   PubMed Web of Science ®Google Scholar
• Olivotto I , CecchiF, PoggesiC, YacoubMH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ. Heart Fail., 5(4), 535–546 (2012).
   PubMed Web of Science ®Google Scholar
• Xiao Y , YangKQ, JiangY, ZhouXL. Recent progress in end-stage hypertrophic cardiomyopathy. Am. J. Med. Sci., 349(5), 448–453 (2015).
   PubMed Web of Science ®Google Scholar
• Masarone D , KaskiJP, PacileoGet al. Epidemiology and clinical aspects of genetic cardiomyopathies. Heart Fail. Clin., 14(2), 119–128 (2018).
   PubMed Web of Science ®Google Scholar
• Marstrand P , HanL, DaySMet al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. Circulation, 141(17), 1371–1383 (2020).
   PubMed Web of Science ®Google Scholar
• Ammirati E , ContriR, CoppiniRet al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur. J. Heart Fail., 18(9), 1106–1118 (2016).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JanuzziJLJr, AllenLAet al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol., 71(2), 201–230 (2018).
   PubMed Web of Science ®Google Scholar
• Lang CC , StruthersAD. Targeting the renin–angiotensin–aldosterone system in heart failure. Nat. Rev. Cardiol., 10(3), 125–134 (2013).
   PubMed Web of Science ®Google Scholar
• Mullens W , DammanK, HarjolaVPet al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail., 21(2), 137–155 (2019).
   PubMed Web of Science ®Google Scholar
• Felker GM , EllisonDH, MullensWet al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol., 75(10), 1178–1195 (2020).
   PubMed Web of Science ®Google Scholar
• Torres MF , Perez-VillaF. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob. Cardiol. Sci. Pract., 12(3), 32–38 (2018).
   Google Scholar
• Pasqualucci D , FornaroA, CastelliGet al. Clinical spectrum, therapeutic options and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ. Heart Fail., 8(6), 1014–1021 (2015).
   PubMed Web of Science ®Google Scholar
• Seferovic PM , PonikowskiP, AnkerSDet al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail., 21(10), 1169–1186 (2019).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr , PrescottMF, ButlerJet al. Association of change in n-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA, 322(11), 1–11 (2019).
   Web of Science ®Google Scholar
• Nandal S , ChowCL, HannahVet al. Tolerability and efficacy of sacubitril/valsartan in clinical practice. Intern. Med. J. doi:10.1111/imj.14749 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar